Advanced search
Publication Cover
Drug Development and Industrial Pharmacy Volume 43, 2017 - Issue 4
Submit an article Journal homepage
208
Views
17
CrossRef citations to date
0
Altmetric
Research Articles

Preparation and in vivo safety evaluations of antileukemic homoharringtonine-loaded PEGylated liposomes

Dong LiuState Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biomedical Sciences and Medical Engineering, Southeast University, Nanjing, P.R. China; ;Center for Traditional Chinese Medicine R&D, West Anhui University, Lu’an, P.R. ChinaView further author information
,
Jing XingState Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biomedical Sciences and Medical Engineering, Southeast University, Nanjing, P.R. China; View further author information
,
Fei XiongState Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biomedical Sciences and Medical Engineering, Southeast University, Nanjing, P.R. China; View further author information
,
Fang YangState Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biomedical Sciences and Medical Engineering, Southeast University, Nanjing, P.R. China; Correspondence[email protected] [email protected]
View further author information
&
Ning GuState Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biomedical Sciences and Medical Engineering, Southeast University, Nanjing, P.R. China; Correspondence[email protected] [email protected]
View further author information
Pages 652-660 | Received 28 Aug 2016, Accepted 17 Dec 2016, Published online: 05 Jan 2017

References

  • Luo CY, Tang JY, Wang YP. Homoharringtonine: a new treatment option for myeloid leukemia. Hematology 2013;9:259–70.
  • Kantarjian HM, Talpaz M, Santini V, et al. Homoharringtonine: history, current research, and future direction. Cancer 2001;92:1591–605.
  • Lü S, Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol 2014;7:2–10.
  • Robin JP, Dhal R, Dujardin G, et al. The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett 1999;40:2931–4.
  • O’Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86:3322–6.
  • Ho ESK, Lam SSY, Man CH,CHER, et al. Bringing an old drug to a new treatment strategy in treating FLT-ITD AML-combination of homoharringtonine and sorafenib. Blood 2014;124:3610.
  • Zhou X, Xu N, Li R, et al. DJ-1 plays an important role in homoharringtonine-induced apoptosis of imatinib-resistant chronic myeloid leukemia cells. Blood 2014;124:5955–6.
  • Cao M, Liu F, Zhang X, et al. The formation of intracellular nanoparticles correlates with cisplatin resistance. Sci China Mater 2015;58:640–8.
  • Liu D, Yang F, Xiong F, et al. The smart drug delivery system and its clinical potential. Theranostics 2016;6:1306–23.
  • Kaasgaard T, Andresen TL. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Deliv 2010;7:225–43.
  • Corvo ML, Mendo AS, Figueiredo S, et al. Liposomes as delivery system of a Sn(IV) complex for cancer therapy. Pharm Res 2016;33:1351–8.
  • Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30:592–9.
  • Shavi GV, Reddy MS, Raghavendra R, et al. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation. J Liposome Res 2015;26:28–46.
  • Xiong F, Chen Y, Chen J, et al. Rubik-like magnetic nanoassemblies as an efficient drug multifunctional carrier for cancer theranostics. J Control Release 2013;172:993–1001.
  • Hood RR, Shao C, Omiatek DM, et al. Microfluidic synthesis of PEG- and folate-conjugated liposomes for one-step formation of targeted stealth nanocarriers. Pharm Res 2013;30:1597–607.
  • Xiong F, Xiong C, Yao J, et al. Preparation, characterization and evaluation of breviscapine lipid emulsions coated with monooleate-PEG-COOH. Int J Pharm 2011;421:275–82.
  • Sunoqrot S, Bugno J, Lantvit D, et al. Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. J Control Release 2014;191:115–22.
  • Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214–21.
  • Jakoby J, Beuschlein F, Mentz S, et al. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects. Oncotarget 2015;6:43698–711.
  • Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 2012;64:316–26.
  • Barenholz YC. Doxil® – the first FDA-approved nano-drug: lessons learned. J Control Release 2012;160:117–34.
  • Li M, Xiong F, Shi FF, et al. Homoharringtonine delivered by high proportion PEG of long-circulating liposomes inhibits RPMI8226 multiple myeloma cells in vitro and in vivo. Am J Transl Res 2016;8:1355–68.
  • Chen C, Han D, Cai C, et al. An overview of liposome lyophilization and its future potential. J Control Release 2010;142:299–311.
  • He J, Cheung AP, Wang E, et al. Stability-indicating LC assay of and impurity identification in homoharringtonine samples. J Pharm Biomed Anal 2000;22:541–54.
  • Lingling G, Yuan Z, Weigen L. Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles. Drug Dev Ind Pharm 2016;42:1325–33.
  • Xiong F, Wang H, Chen YJ, et al. Characterization, biodistribution and targeting evaluation of breviscapine lipid emulsions following intravenous injection in mice. Drug Deliv 2011;18:159–65.
  • Chang M, Lu S, Zhang F, et al. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting. Colloids Surf B Biointerfaces 2015;129:175–82.
  • He D, Yin S, Han F, et al. Pharmacokinetics and tissue distribution of two novel isomerism anticancer platinum compounds. Drug Dev Ind Pharm 2016;42:1792–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.